Emergent BioSolutions (EBS) Total Debt (2010 - 2026)

Emergent BioSolutions' Total Debt history runs 17 years deep, the most recent figure standing at $573.6 million for Q1 2026.

• On a quarterly basis, Total Debt fell 13.84% year-over-year to $573.6 million in Q1 2026; TTM through Mar 2026 was $573.6 million, a 13.84% decrease from a year earlier, with the FY2025 full-year figure at $572.1 million, down 13.8% from the prior year.
• Total Debt steadied at $573.6 million in Q1 2026 per EBS's latest filing, from $572.1 million in the prior quarter.
• Across five years, Total Debt topped out at $1.0 billion in Q3 2022 and bottomed at $446.5 million in Q4 2023.
• The 5-year median for Total Debt is $693.1 million (2025), against an average of $691.1 million.
• Across the five-year window, Total Debt slumped 56.57% in 2023 and jumped 103.08% in 2024, its largest moves.
• Year by year, Total Debt stood at $448.5 million in 2022, then retreated by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then retreated by 13.8% to $572.1 million in 2025, then climbed by 0.26% to $573.6 million in 2026.
• Per Business Quant, the three latest EBS Total Debt figures stand at $573.6 million (Q1 2026), $572.1 million (Q4 2025), and $693.1 million (Q3 2025).